EP 1173551 A2 20020123 - PSEUDOTYPED RETROVIRAL VECTOR FOR GENE THERAPY OF CANCER
Title (en)
PSEUDOTYPED RETROVIRAL VECTOR FOR GENE THERAPY OF CANCER
Title (de)
PSEUDOTYPISIERTE RETROVIRALE VEKTOREN ZUR GENTHERAPIE GEGEN KREBS
Title (fr)
PSEUDOTYPE DE VECTEUR RETROVIRAL DESTINE A LA THERAPIE GENIQUE DU CANCER
Publication
Application
Priority
- CA 0000445 W 20000420
- US 13068099 P 19990423
Abstract (en)
[origin: WO0065034A2] The invention relates to retroviral expression vectors and more particularly to pseudotyped retroviral vectors for gene therapy of cancer. Direct in vivo tumor-targeting with "suicide" viral vectors is limited by inefficient gene transfer and indiscriminate transfer of a contitionally toxic gene to surrounding non-malignant tissue. Retrovectors pseudotyped with a Vesicular Stomatitis Virus G protein (VSVG) may serve as a remedy to this conundrum. These retroviral particles differ from standard murine retroviruses by their very broad tropism and the capacity to be concentrated by ultracentrifugation without loss of activity. A VSVG-typed retrovector can be utilized for efficient and tumor specific Herpes Simplex Virus Thymidine Kinase (TK) gene delivery in vivo. A bicistronic retroviral vector which expresses TK and Green Fluorescence Protein (pTKiGFP) was constructed.
IPC 1-7
C12N 7/01; C12N 15/86; C12N 15/85; C12N 15/63; C12N 5/10; A61K 48/00; C12Q 1/68
IPC 8 full level
A61K 47/48 (2006.01); C07K 14/145 (2006.01); C12N 7/04 (2006.01); C12N 15/867 (2006.01); A61K 48/00 (2006.01)
CPC (source: EP)
A61K 47/6901 (2017.07); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 48/00 (2013.01); C12N 2740/13043 (2013.01); C12N 2740/13062 (2013.01); C12N 2760/20222 (2013.01); C12N 2840/203 (2013.01)
Citation (search report)
See references of WO 0065034A2
Citation (examination)
- WO 9604934 A1 19960222 - GENETIC THERAPY INC [US], et al
- WO 9429440 A1 19941222 - UNIV CALIFORNIA [US]
- WO 9635454 A1 19961114 - ST JUDE CHILDRENS RES HOSPITAL [US], et al
- YEE J.-K. ET AL.: "Generation of High-Titer Pseudotyped Retroviral Vectors with Very Broad Host Range", METHODS IN CELL BIOLOGY, vol. 43, 1994, pages 99 - 112
- YANG Y ET AL.: "Inducible, High-Level Production of Infectious Murine Leukemia Retroviral Particles Pseudotyped with Vesicular Stomatitis Virus G Envelope Protein", HUMAN GENE THERAPY, vol. 6, September 1995 (1995-09-01), pages 1203 - 1213
- WANG S. ET AL.: "Development of a VSV-G protein pseudotyped retroviral vector system expressing dominant oncogenes from a lacO-modified inducible LTR promoter", GENE, vol. 182, 1996, pages 145 - 150
- GALLARDO ET AL.: "Recombinant Retroviruses Pseudotyped with the Vesicular Stomatitis Virus G Glycoprotein Mediate Both STable Gene Transfer and Pseudotransduction in Human Peripheral Blood Lymphocytes", BLOOD, vol. 90, no. 3, 1 August 1997 (1997-08-01), pages 952 - 957
- ORY D S ET AL.: "A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes", PROC.NATL.ACAD.SCI., vol. 93, October 1996 (1996-10-01), pages 11400 - 11406
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 0065034 A2 20001102; WO 0065034 A3 20010125; AU 4096100 A 20001110; CA 2371216 A1 20001102; EP 1173551 A2 20020123
DOCDB simple family (application)
CA 0000445 W 20000420; AU 4096100 A 20000420; CA 2371216 A 20000420; EP 00920308 A 20000420